From: Triple-negative breast cancer molecular subtyping and treatment progress
TNBC subtype | Therapeutic strategies | Therapeutic targeted drugs |
---|---|---|
BL1 (basal-like 1) | Inhibit cell proliferation and DNA damage response | Mitosis inhibitors (Paclitaxel, Docetaxel, Ixabepilone, Nab-Paclitaxel, Vinorelbine) Cytostatics (Cisplatin, Carboplatin, Nedaplatin, Eptaplatin, Oxaliplatin, Lobaplatin, Satraplatin, Mercaptopurine) PARP inhibitors (Olaparib, Rucaparib, Talazoparib, Niraparib) DNA Synthetic inhibitors (Topotecan, Irinotecan, Camptothecin, Doxorubicin, Daunorubicin, Mitomycin) |
BL2 (basal-like 2) | Inhibit TP63, EGFR, and MET signaling | Cytostatics (Cisplatin, Carboplatin, Nedaplatin, Eptaplatin, Oxaliplatin, Lobaplatin, Satraplatin, Mercaptopurine) PARP inhibitors (Olaparib, Rucaparib, Talazoparib and Niraparib) Growth Factor inhibitors (Erlotinib, Gefitinib, Afatinib, Osimertinib, Olmutinib, Nazartinib, Avitinib, lapatinib, Cetuximab, Panitumumab, Vandetanib, Bevacizumab, Pertuzumab, Ramucirumab, Trastuzumab, Axitinib, Cabozantinib, Ceritinib, Crizotinib, Lenvatinib, Nilotinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib) mTOR inhibitors (rapamycin, everolimus, RapaLink-1) |
IM (immunomodulatory) | Inhibit immune signaling | Cytostatics (Cisplatin, Carboplatin, Nedaplatin, Eptaplatin, Oxaliplatin, Lobaplatin, Satraplatin, Mercaptopurine) PARP inhibitors (Olaparib, Rucaparib, Talazoparib and Niraparib) Immune checkpoint inhibitors (Ipilimumab, Nivolumab) |
M (mesenchymal) | Inhibit EMT, Wnt, PI3K, mTOR, Scr, TGFβ, IGF1R, Notch | Growth Factor inhibitors (Erlotinib, Gefitinib, Afatinib, Osimertinib, Olmutinib, Nazartinib, Avitinib, lapatinib, Cetuximab, Panitumumab, Vandetanib, Bevacizumab, Pertuzumab, Ramucirumab, Trastuzumab, Axitinib, Cabozantinib, Ceritinib, Crizotinib, Lenvatinib, Nilotinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib) mTOR inhibitors (Rapamycin, Everolimus, RapaLink-1) Scr inhibitors (Bosutinib, Dasatinib) PI3K inhibitors (Idelalisib) |
MSL (mesenchymal stem-like) | Inhibit EMT, Wnt, TGFβ, MAPK, Rac, PI3K, mTOR, Scr, PDGF | Growth Factor inhibitors (Erlotinib, Gefitinib, Afatinib, Osimertinib, Olmutinib, Nazartinib, Avitinib, lapatinib, Cetuximab, Panitumumab, Vandetanib, Bevacizumab, Pertuzumab, Ramucirumab, Trastuzumab, Axitinib, Cabozantinib, Ceritinib, Crizotinib, Lenvatinib, Nilotinib, Pazopanib, Regorafenib, Sorafenib, Sunitinib) mTOR inhibitors (rapamycin, everolimus, RapaLink-1) PI3K inhibitors (Idelalisib) MAPK inhibitors (Trametinib, Dabrafenib) Scr inhibitors (Bosutinib, Dasatinib) |
LAR (luminal androgen receptor) | Inhibit AR signaling, FOXA1, and ERBB4 signaling | Nonsteroidal antiandrogens (bicalutamide) mTOR inhibitors (rapamycin, everolimus, RapaLink-1) PI3K inhibitors (Idelalisib) |